SCHEMBL3098904

SCHEMBL3098904

BrCc1cccc(C(c2ccccc2)c2cccc(CBr)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.52
ALDH1A1 P00352 1/20 0.52
TSHR P16473 1/20 0.52
SLC6A2 P23975 5/20 0.40
SLC6A4 P31645 4/20 0.40
SLC6A3 Q01959 4/20 0.40
TDP1 Q9NUW8 1/20 0.38
CFTR P13569 1/20 0.36
GOPC Q9HD26 1/20 0.36
LOXL2 Q9Y4K0 1/20 0.36
TAAR1 Q96RJ0 2/20 0.34
MAOA P21397 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
CYP2A6 P11509 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
CES2 O00748 2/20 0.34
CES1 P23141 2/20 0.34
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102914 0.86 HTR2A (0.40) TRPA1ALDH1A1TSHRSLC6A2SLC6A4
SCHEMBL3094551 0.85 TRPA1 (0.35) TRPA1ALDH1A1TSHRTAAR1
SCHEMBL3107525 0.85 ALDH1A1 (0.35) TRPA1ALDH1A1TSHRTDP1LOXL2
SCHEMBL3107011 0.82 TSHR (0.42) TSHRTAAR1
SCHEMBL2201031 0.81 TRPA1 (0.48) TRPA1ALDH1A1TSHRSLC6A2SLC6A4
SCHEMBL3108222 0.80 TSHR (0.59) TRPA1ALDH1A1TSHRSLC6A2SLC6A4
SCHEMBL3188682 0.78 TSHR (0.44) TRPA1ALDH1A1TSHRTDP1CES2
SCHEMBL3094564 0.77 SLC6A3 (0.58) TRPA1ALDH1A1TSHRSLC6A2SLC6A4
SCHEMBL15094029 0.77 DAO (0.45) TRPA1ALDH1A1TSHR
SCHEMBL29413218 0.77 DAO (0.45) TRPA1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2163553-B1 ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO LTD (CN) 2013-12-25 EP disclosed
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 US disclosed
EP-2163553-A1 ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF Beijing Molecule Science and Technology Co., Ltd. (CN) 2010-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof SRM, SP1, SMS TRPA1 2346/4885ALDH1A1 1826/4885TSHR 3711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.